Previous 10 | Next 10 |
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives PR Newswire – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, En...
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announc...
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1) PR Newswire Bioma...
2023-11-29 18:48:21 ET Summary Selinexor has received three approvals but has faced disappointing sales due to competition and toxicity. Nevertheless, an already established global commercial infrastructure will support the launch of additional indications. Selinexor is being eval...
2023-11-06 10:12:23 ET More on Karyopharm Therapeutics Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0...
2023-11-02 15:30:24 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q3 2023 Earnings Call Nov 02, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q3 2023 Earnings C...
2023-11-02 14:25:25 ET Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call November 2, 2023, 08:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chi...
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH) PR Newswire Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass. , Nov. 2, 2023 /PRNewswire...
2023-11-02 07:33:14 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm Therapeutics Q3 2023 Earnings Preview Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myelo...
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – ȁ...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...